Teva Secures $500 Million Partnership to Accelerate New Vitiligo Therapy

Tel Aviv, Sunday, 11 January 2026.
Royalty Pharma commits up to $500 million to fast-track Teva’s immune-regulating antibody, explicitly targeting a 2026 start for Phase 2b trials to treat vitiligo patients.